Competition of SARS-CoV-2 variants on the pandemic transmission dynamics

被引:10
作者
Chen, Jiaqi [1 ]
Gu, Changgui [1 ]
Ruan, Zhongyuan [2 ]
Tang, Ming [3 ,4 ]
机构
[1] Univ Shanghai Sci & Technol, Business Sch, Dept Syst Sci, Shanghai 200093, Peoples R China
[2] Zhejiang Univ Technol, Inst Cyberspace Secur, Hangzhou 310023, Peoples R China
[3] East China Normal Univ, Sch Phys & Elect Sci, Shanghai 200241, Peoples R China
[4] East China Normal Univ, Shanghai Key Lab Multidimens Informat Proc, Shanghai 200241, Peoples R China
基金
上海市自然科学基金; 中国国家自然科学基金;
关键词
Competition between strains; Cross-immunity; Future variants; Periodicity; Resurgence of the previous strain; INFLUENZA; VACCINE;
D O I
10.1016/j.chaos.2023.113193
中图分类号
O1 [数学];
学科分类号
0701 ; 070101 ;
摘要
SARS-CoV-2 has produced various variants during its ongoing evolution. The competitive behavior driven by the co-transmission of these variants has influenced the pandemic transmission dynamics. Therefore, studying the impact of competition between SARS-CoV-2 variants on pandemic transmission dynamics is of considerable practical importance. In order to formalize the mechanism of competition between SARS-CoV-2 variants, we propose an epidemic model that takes into account the co-transmission of competing variants. The model focuses on how cross-immunity influences the transmission dynamics of SARS-CoV-2 through competitive mechanisms between strains. We found that inter-strain competition affects not only both the final size and the replacement time of the variants, but also the invasive behavior of new variants in the future. Due to the limited extent of cross-immunity in previous populations, we predict that the new strain may infect the largest number of individuals in China without control interventions. Moreover, we also observed the possibility of periodic outbreaks in the same lineage and the possibility of the resurgence of previous lineages. Without the invasion of a new variant, the previous variant (Delta variant) is projected to resurgence as early as 2023. However, its resurgence may be prevented by a new variant with a greater competitive advantage.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] SARS-Cov-2: The Relevance and Prevention of Aerosol Transmission
    van der Valk, Johanna P. M.
    In 't Veen, Johannes C. C. M.
    JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2021, 63 (06) : E395 - E401
  • [32] Tear antibodies to SARS-CoV-2: implications for transmission
    Selva, Kevin J.
    Davis, Samantha K.
    Haycroft, Ebene R.
    Lee, Wen Shi
    Lopez, Ester
    Reynaldi, Arnold
    Davenport, Miles P.
    Kent, Helen E.
    Juno, Jennifer A.
    Chung, Amy W.
    Kent, Stephen J.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (11)
  • [33] Transplacental Transmission of SARS-CoV-2: A Narrative Review
    Bui, Minh Tien
    Le, Cam Anh Nguyen
    Duong, Khanh Linh
    Hoang, Van Thuan
    Nguyen, Trung Kien
    MEDICINA-LITHUANIA, 2024, 60 (09):
  • [34] SARS-CoV-2: phenotype, genotype, and characterization of different variants
    Mohammadreza Saberiyan
    Elham Karimi
    Zahra Khademi
    Parvaneh Movahhed
    Amir Safi
    Ameneh Mehri-Ghahfarrokhi
    Cellular & Molecular Biology Letters, 2022, 27
  • [35] The biological and clinical significance of emerging SARS-CoV-2 variants
    Tao, Kaiming
    Tzou, Philip L.
    Nouhin, Janin
    Gupta, Ravindra K.
    de Oliveira, Tulio
    Kosakovsky Pond, Sergei L.
    Fera, Daniela
    Shafer, Robert W.
    NATURE REVIEWS GENETICS, 2021, 22 (12) : 757 - 773
  • [36] The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom
    Wu, Jiajing
    Zhang, Li
    Zhang, Yue
    Wang, Haixin
    Ding, Ruxia
    Nie, Jianhui
    Li, Qianqian
    Liu, Shuo
    Yu, Yongxin
    Yang, Xiaoming
    Duan, Kai
    Qu, Xiaowang
    Wang, Youchun
    Huang, Weijin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [37] SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
    Singh, Desh Deepak
    Parveen, Amna
    Yadav, Dharmendra Kumar
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [38] Defining the risk of SARS-CoV-2 variants on immune protection
    DeGrace, Marciela M.
    Ghedin, Elodie
    Frieman, Matthew B.
    Krammer, Florian
    Grifoni, Alba
    Alisoltani, Arghavan
    Alter, Galit
    Amara, Rama R.
    Baric, Ralph S.
    Barouch, Dan H.
    Bloom, Jesse D.
    Bloyet, Louis-Marie
    Bonenfant, Gaston
    Boon, Adrianus C. M.
    Boritz, Eli A.
    Bratt, Debbie L.
    Bricker, Traci L.
    Brown, Liliana
    Buchser, William J.
    Carreno, Juan Manuel
    Cohen-Lavi, Liel
    Darling, Tamarand L.
    Davis-Gardner, Meredith E.
    Dearlove, Bethany L.
    Di, Han
    Dittmann, Meike
    Doria-Rose, Nicole A.
    Douek, Daniel C.
    Drosten, Christian
    Edara, Venkata-Viswanadh
    Ellebedy, Ali
    Fabrizio, Thomas P.
    Ferrari, Guido
    Fischer, Will M.
    Florence, William C.
    Fouchier, Ron A. M.
    Franks, John
    Garcia-Sastre, Adolfo
    Godzik, Adam
    Gonzalez-Reiche, Ana Silvia
    Gordon, Aubree
    Haagmans, Bart L.
    Halfmann, Peter J.
    Ho, David D.
    Holbrook, Michael R.
    Huang, Yaoxing
    James, Sarah L.
    Jaroszewski, Lukasz
    Jeevan, Trushar
    Johnson, Robert M.
    NATURE, 2022, 605 (7911) : 640 - 652
  • [39] Vaccines against SARS-CoV-2 variants and future pandemics
    Park, Taeyoung
    Hwang, Hyogyeong
    Moon, Suhyeong
    Kang, Sang Gu
    Song, Seunghyup
    Kim, Young Hun
    Kim, Hanbi
    Ko, Eun-Ju
    Yoon, Soon-Do
    Kang, Sang-Moo
    Hwang, Hye Suk
    EXPERT REVIEW OF VACCINES, 2022, 21 (10) : 1363 - 1376
  • [40] SARS-CoV-2: Evolution and Emergence of New Viral Variants
    Flores-Vega, Veronica Roxana
    Monroy-Molina, Jessica Viridiana
    Jimenez-Hernandez, Luis Enrique
    Torres, Alfredo G.
    Santos-Preciado, Jose Ignacio
    Rosales-Reyes, Roberto
    VIRUSES-BASEL, 2022, 14 (04):